MX375073B - Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico. - Google Patents

Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico.

Info

Publication number
MX375073B
MX375073B MX2017006000A MX2017006000A MX375073B MX 375073 B MX375073 B MX 375073B MX 2017006000 A MX2017006000 A MX 2017006000A MX 2017006000 A MX2017006000 A MX 2017006000A MX 375073 B MX375073 B MX 375073B
Authority
MX
Mexico
Prior art keywords
fluoropyrrolidine
cyclopropylamino
dihydroquinoline
fluoroethyl
oxo
Prior art date
Application number
MX2017006000A
Other languages
English (en)
Inventor
Akinori Goto
Ichiro Araya
Keiko Funada
Muneki Nagao
Wataru Minagawa
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of MX375073B publication Critical patent/MX375073B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe una técnica para mejorar la solubilidad en agua y estabilidad de almacenamiento de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico (compuesto (1)) que es seguro y no solamente tiene una fuerte acción antibacteriana sino también es efectiva para bacterias resistentes para las cuales agentes antibacterianos convencionales son menos efectivos. Se proporcionan cristales de la sal de clorhidrato del compuesto (1), cristales de la sal de clorhidrato hidratada del compuesto (1), y cristales de la sal de metansulfonato del compuesto (1). En estos cristales, se elimina la descomposición debido a influencias de luz en comparación a la misma en cristales libres del compuesto (1), y su estabilidad de almacenamiento es alta. Estos cristales tienen solubilidad más alta en el agua que los cristales libres del compuesto (1).
MX2017006000A 2011-11-10 2012-11-09 Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico. MX375073B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2012071739 2012-03-27
PCT/JP2012/007195 WO2013069297A1 (ja) 2011-11-10 2012-11-09 ７－｛（３s、４s）－３－［（シクロプロピルアミノ)メチル］－４－フルオロピロリジン－1－イル｝－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１、４－ジヒドロキノリン－３－カルボン酸の結晶

Publications (1)

Publication Number Publication Date
MX375073B true MX375073B (es) 2025-03-06

Family

ID=48289529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006000A MX375073B (es) 2011-11-10 2012-11-09 Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico.

Country Status (17)

Country Link
US (3) US9090587B2 (es)
EP (2) EP3112359B1 (es)
JP (4) JP5871948B2 (es)
KR (2) KR102162208B1 (es)
CN (2) CN103930414B (es)
AU (1) AU2016273899B2 (es)
BR (1) BR112014010765B1 (es)
CA (1) CA2855022C (es)
ES (2) ES2621664T3 (es)
IN (1) IN2014DN03277A (es)
MX (1) MX375073B (es)
NZ (1) NZ623808A (es)
RU (2) RU2017109814A (es)
SA (1) SA112330992B1 (es)
SG (2) SG10201608167UA (es)
TW (1) TWI547492B (es)
WO (1) WO2013069297A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2014174848A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 錠剤
US9603804B2 (en) 2013-04-25 2017-03-28 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2014174847A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP6018334B2 (ja) * 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物
EP3210608A4 (en) * 2014-10-23 2018-06-20 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
SG10201908007UA (en) * 2015-03-13 2019-10-30 Kyorin Pharmaceutical Co Ltd Respiratory infection treating agent
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
WO2016195020A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
WO2018230686A1 (ja) 2017-06-16 2018-12-20 杏林製薬株式会社 誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤
BR112019025960A2 (pt) 2017-06-16 2020-11-03 Kyorin Pharmaceutical Co., Ltd. agente terapêutico para pneumonia aspirativa, supuração pulmonar ou abcesso pulmonar
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003076428A1 (en) * 2002-03-08 2003-09-18 Daiichi Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivative
SI1666477T1 (sl) 2003-09-10 2013-10-30 Kyorin Pharmaceutical Co., Ltd. Derivati 7-(4-substituiran 3-ciklopropilaminometil-1-pirolidinil) kinolonkarboksilne kisline
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
CN103930414B (zh) 2016-01-20
EP2778159B1 (en) 2017-03-01
ES2621664T3 (es) 2017-07-04
AU2016273899B2 (en) 2017-07-27
IN2014DN03277A (es) 2015-05-22
SG10201608167UA (en) 2016-11-29
JP2018158949A (ja) 2018-10-11
USRE47785E1 (en) 2019-12-31
US9328089B2 (en) 2016-05-03
JP2017160243A (ja) 2017-09-14
AU2016273899A1 (en) 2017-01-12
CN103930414A (zh) 2014-07-16
RU2017109814A3 (es) 2020-04-08
JPWO2013069297A1 (ja) 2015-04-02
US9090587B2 (en) 2015-07-28
AU2012337206B2 (en) 2016-09-15
BR112014010765B1 (pt) 2020-07-14
TWI547492B (zh) 2016-09-01
AU2012337206A1 (en) 2014-05-22
JP5871948B2 (ja) 2016-03-01
KR20140098074A (ko) 2014-08-07
WO2013069297A1 (ja) 2013-05-16
KR102162208B1 (ko) 2020-10-06
EP3112359B1 (en) 2019-08-21
JP2016027045A (ja) 2016-02-18
TW201332991A (zh) 2013-08-16
RU2615509C2 (ru) 2017-04-05
BR112014010765A2 (pt) 2017-06-13
JP6818719B2 (ja) 2021-01-20
CA2855022C (en) 2019-05-07
SA112330992B1 (ar) 2015-09-13
KR20190065456A (ko) 2019-06-11
CA2855022A1 (en) 2013-05-16
SG11201401817TA (en) 2014-08-28
NZ623808A (en) 2015-07-31
RU2014123567A (ru) 2015-12-20
CN104945375A (zh) 2015-09-30
JP6514069B2 (ja) 2019-05-15
EP2778159A4 (en) 2015-06-03
US20150284361A1 (en) 2015-10-08
CN104945375B (zh) 2017-07-04
AU2012337206A8 (en) 2016-09-22
RU2017109814A (ru) 2019-01-23
US20140288310A1 (en) 2014-09-25
EP3112359A1 (en) 2017-01-04
EP2778159A1 (en) 2014-09-17
JP6349435B2 (ja) 2018-06-27
ES2747303T3 (es) 2020-03-10

Similar Documents

Publication Publication Date Title
MX375073B (es) Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico.
NZ734896A (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
IN2014MN02106A (es)
BR112013002182A2 (pt) derivados de quinolina e inibidores de melk contendo os mesmos
PH12016500169A1 (en) Polymorph of syk inhibitors
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
PT2411396E (pt) Derivados de tienopirimidinadiona como moduladores de trpa1
SA515361086B1 (ar) Fasn مركبات وتركيبات جديدة لتثبيط
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
WO2012131710A3 (en) Novel process for the synthesis of indoline derivatives
WO2013098836A8 (en) A bis-quinophthalone pigment and a process for preparing the same
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
IN2015DN02424A (es)
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
UA117849C2 (uk) Спосіб одержання 3-заміщених складних ефірів (індол-1-іл)-оцтової кислоти
MX347693B (es) Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico.
MX2015017864A (es) Metodo de preparacion de derivados de acido pirrolidina-2-carboxil ico.
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
PH12012502478A1 (en) Isoquinoline derivative
EA201201385A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MY168434A (en) Novel acetic acid ester compound or salt thereof
EA201400269A1 (ru) Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина
GEP20156369B (en) New process for synthesis of ivabradine and addition salts therewith pharmaceutically acceptable acid